Prifetrastat
Based on 1 Customer Validation
Prifetrastat (PF-07248144), a first-in-class, selective, and orally active KAT6A and KAT6AB inhibitor. Prifetrastat can be used for the study of ER+/HER2− breast cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.63%
- CAS. Nr.: 2569008-99-5
- Formel: C19H18N4O5S
- Molecular Weight:414.44
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-132283
PF-9363KAT6A/KAT6B Inhibitor -
HY-102058
WM-1119KAT6A Inhibitor -
HY-134901
WM-3835HBO1 Inhibitor -
HY-154944
JG-2016HAT1 Inhibitor -
HY-102059
MOZ-IN-2MOZ Inhibitor -
HY-111784
Inobrodibp300/CBP Inhibitor -
HY-102060
WM-8014MOZ Inhibitor -
HY-16706A
Remodelin hydrobromideNAT10 Inhibitor -
HY-16706
RemodelinHistone Acetyltransferase Inhibitor -
HY-13823
C646p300/CBP HAT Inhibitor -
HY-124696
PU139HAT Inhibitor -
HY-129039
Butyrolactone 3Gcn5 Inhibitor
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
GCN5/PCAF |
In Vitro
Prifetrastat (compound E) exhibits synergistic inhibitory effects in cancer cells T47D, ZR-75-1, CAMA1 and MCF7 with combination of Palbociclib (HY-50767)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mouse ST340 xenograft model[2]
-
Dosage:3 mg/kg
-
Administration:po, QD for 21 days
-
Result:Inhibited tumor growth with a TGI of 55.4%.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 2569008-99-5
-
Appearance Solid
-
Molecular Weight 414.44
-
Formel C19H18N4O5S
-
Color White to off-white
-
SMILES
O=S(NC1=NOC2=CC(CN3N=CC=C3)=CC(OC)=C21)(C4=C(OC)C=CC=C4)=O
-
Synonyms
PF-07248144
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 4 mg/mL (9.65 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4129 mL | 12.0645 mL | 24.1289 mL | 60.3224 mL |
| 5 mM | 0.4826 mL | 2.4129 mL | 4.8258 mL | 12.0645 mL |
Prifetrastat Related Classifications
HY-153444 Related Classifications
Powered by Bioz